MedTrace Logo

ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT01208090 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 326

Last updated 2025-03-30

No results posted yet for this study

Summary

This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.

Conditions

Interventions

DRUG

ACT-128800

ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily

DRUG

Placebo

ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily

Sponsors & Collaborators

  • Actelion

    lead INDUSTRY

Principal Investigators

  • Actelion Pharmaceuticals · Actelion

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2012-10-31
Completion
2012-11-30

Countries

  • Austria
  • Belgium
  • Bulgaria
  • Czechia
  • Denmark
  • France
  • Hungary
  • Italy
  • Lithuania
  • Romania
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • Switzerland
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01208090 on ClinicalTrials.gov